Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $2,435,400.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00. Following the completion of the sale, the chief executive officer owned 666,195 shares in the company, valued at $54,081,710.10. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, February 25th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.26, for a total value of $2,707,800.00.

Kymera Therapeutics Price Performance

Shares of KYMR stock opened at $80.71 on Friday. Kymera Therapeutics, Inc. has a 1 year low of $28.06 and a 1 year high of $103.00. The stock’s 50 day simple moving average is $84.52 and its two-hundred day simple moving average is $76.23. The company has a market cap of $6.59 billion, a PE ratio of -21.93 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 26.69% and a negative net margin of 611.94%.The business had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same period in the prior year, the business posted ($0.82) earnings per share. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. Equities research analysts expect that Kymera Therapeutics, Inc. will post -3.65 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on KYMR. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Stephens upped their price objective on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Jefferies Financial Group began coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective on the stock. Royal Bank Of Canada restated an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Finally, BTIG Research decreased their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.70.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Fifth Third Bancorp bought a new position in shares of Kymera Therapeutics during the first quarter valued at approximately $4,268,000. Keudell Morrison Wealth Management grew its stake in shares of Kymera Therapeutics by 5.9% during the first quarter. Keudell Morrison Wealth Management now owns 6,990 shares of the company’s stock valued at $582,000 after buying an additional 390 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in shares of Kymera Therapeutics by 21,538.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 25,533 shares of the company’s stock valued at $1,987,000 after buying an additional 25,415 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Kymera Therapeutics during the fourth quarter valued at approximately $198,000. Finally, Virtu Financial LLC bought a new position in shares of Kymera Therapeutics during the fourth quarter valued at approximately $2,123,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.